Cargando…

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives

Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reverdy, Thibaut, Sajous, Christophe, Péron, Julien, Glehen, Olivier, Bakrin, Naoual, Gertych, Witold, Lopez, Jonathan, You, Benoit, Freyer, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564452/ https://www.ncbi.nlm.nih.gov/pubmed/32854393 http://dx.doi.org/10.3390/cancers12092414

Ejemplares similares

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
por: Varnier, Romain, et al.
Publicado: (2021)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review
por: Lauby, Ambroise, et al.
Publicado: (2021)

Methods and Designs of Modern Breast Cancer Confirmatory Trials
por: Péron, Julien, et al.
Publicado: (2021)

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)
por: Colomban, Olivier, et al.
Publicado: (2020)

Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses
por: Souadka, Amine, et al.
Publicado: (2022)

Adherence to French and ESGO Quality Indicators in Ovarian Cancer Surgery: An Ad-Hoc Analysis from the Prospective Multicentric CURSOC Study
por: Alejandra, Martinez, et al.
Publicado: (2021)

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study
por: Péron, Julien, et al.
Publicado: (2021)

Localized chemotherapy approaches and advanced drug delivery strategies: a step forward in the treatment of peritoneal carcinomatosis from ovarian cancer
por: Breusa, Silvia, et al.
Publicado: (2023)

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer
por: Hamizi, Salima, et al.
Publicado: (2013)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
por: Essadi, Ismail, et al.
Publicado: (2023)

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Maillet, Denis, et al.
Publicado: (2021)

Impact of the First Wave of the COVID-19 Pandemic on the Lyon University Hospital Cancer Institute (IC-HCL)
por: Belmont, Anne-Sophie, et al.
Publicado: (2021)

Ovarian cancer in the older patient: where are we now? What to do next?
por: Rousseau, Frédérique, et al.
Publicado: (2023)

Early Preinvasive Lesions in Ovarian Cancer
por: Chene, Gautier, et al.
Publicado: (2014)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement—A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO
por: Bengrine, Leila, et al.
Publicado: (2022)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients
por: Kefleyesus, Amaniel, et al.
Publicado: (2023)

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups
por: Gomes David, Manuel, et al.
Publicado: (2022)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Current status of maintenance therapy for advanced ovarian cancer
por: Hope, Joanie Mayer, et al.
Publicado: (2010)

Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France
por: Le Saux, Olivia, et al.
Publicado: (2015)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
por: You, Benoit, et al.
Publicado: (2022)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

Developing a core set of patient-reported outcomes and patient-reported experience measures for peritoneal surface malignancies (COMETE)
por: Taibi, Abdelkader, et al.
Publicado: (2023)

Technique of pressurized intrathoracic aerosol chemotherapy (PITAC) for malignant pleural effusion
por: Drevet, Gabrielle, et al.
Publicado: (2020)

Advancing front of old-age human survival
por: Zuo, Wenyun, et al.
Publicado: (2018)

Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy
por: Milani, Andrea, et al.
Publicado: (2017)

Relationship between time‐to‐isolation and freeze duration: Computational modeling of dosing for Arctic Front Advance and Arctic Front Advance Pro cryoballoons
por: Getman, Michael K., et al.
Publicado: (2019)

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer
por: Goh, Jeffrey C.H., et al.
Publicado: (2022)

PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
por: Bakrin, Naoual, et al.
Publicado: (2018)

Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
por: Shi, Tingyan, et al.
Publicado: (2019)

Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy
por: Nagano, Hiroaki, et al.
Publicado: (2016)

Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
por: DiSilvestro, Paul, et al.
Publicado: (2021)

GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study
por: Glehen, Olivier, et al.
Publicado: (2014)

Advances in understanding genome maintenance
por: Miller, Kyle M
Publicado: (2010)

Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study
por: Bellier, Charlotte, et al.
Publicado: (2023)

Maintenance of mid-latitude oceanic fronts by mesoscale eddies
por: Jing, Zhao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c8dfmgd9q0gbdnjhtgr1blbgq3